Recent studies have reported conflicting levels of tumour cell contamination in PBSC harvests. Radioactive fingerprinting PCR techniques for the immunoglobulin heavy A flow cytometric technique has been developed to detect individual plasma cells in PBSC harvests and to chain genes have found tumour cell contamination in 36% ؊ ) plasma cells and light chain expression in 86% chain restriction can be used as a surrogate marker of clonality. We also wished to correlate light chain restriction and of patients studied. This study has demonstrated that the majority of plasma cells in PBSC harvests from CD19/CD56 expression which has been reported to be a marker of malignant plasma cells.
and 44% 6 of harvests. However when patient-specific oliestablish light chain restriction as a surrogate marker of their clonality. Plasma cells were identified by high gonucleotide primers were used, 100% of patient samples were PCR positive for tumour cells even after a double intensity CD38 (CD38 ؉؉ ) and cytoplasmic immunoglobulin (cIg) expression. The ratio of cytoplasmic kappa to transplant. 7 Gazitt et al 8 
sorted PBSC harvests for CD34
ϩ
Lin
Ϫ Thy ϩ cells and demonstrated by PCR a 2.7 to lambda expression was used to detect light chain restriction. All 25 PBSC harvests studied contained 7.3 log reduction of tumour cells was possible. 8 In this study there were no plasma cells detected by flow cytome-CD38 ؉؉ /cIg plasma cells (mean 0.7%, range 0.03-2%). Harvests from non-myeloma patients also contained try based on the presence of CD38 bright cells in the sorted population. In contrast, another study found that after the plasma cells (mean 0.4%, range 0.01-1.5%). Most of the plasma cells detected in the harvests from myeloma cells were sorted for CD34 ϩ on a magnetic column followed by flow activated cell sorting, no malignant cells patients were immature (CD45 ؉
/CD45
؉؉ ) rather than mature (CD45 ؊ ). When the total plasma cell population could be detected by patient-specific oligonucleotide PCR. 9 While these PCR methods are extremely sensitive for was studied, definite isotype restriction could be detected in only 16% of harvests. Light chain restriction detecting specific tumour cell populations they have limited ability to quantitate cell numbers and analyse individual was found in 53% of harvests when the mature plasma cells (CD45 12 Five patients failed to provide sufor PERCP) were collected for each sample. The data was ficient CD34
ϩ cells and were not eligible for transplananalysed on a remote workstation using Coulter Elite V.4 tation. Currently, 19 patients have been transplanted. software. an average CD38 ϩϩ /cIg expression of 98.3% (range 95-number of CD38 ϩϩ cells for both myeloma and non-mye-99.7%). The same technique was applied to PBSC harvests loma samples. The non-myeloma patients tended to have from patients with myeloma. Figure 2 shows histograms fewer CD38 ϩϩ cells in their PBSC harvests (mean = 0.4%, from a PBSC harvest in which the CD38 ϩϩ cells were also range 0.01-1.5%) but this was not statistically significant cytoplasmic Ig positive. However in this specimen signifi-(t = Ϫ0.7, P = 0.5). We also evaluated the absolute numbers cant numbers of both kappa and lambda cells were present of plasma cells found in PBSC harvests from myeloma (/ ratio = 2.0). patients, the mean was 2.5 ϫ 10 7 CD38
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ϩϩ /l, range 3.1 ϫ 10 6 -9.3 ϫ 10 7 CD38
ϩϩ . In non-myeloma harvests the mean absolute number of plasma cells was 3.4 ϫ 10 7
Frequency of plasma cells in PBSC harvests CD38
ϩϩ /l, range 7.8 ϫ 10 5 -1.3 ϫ 10 8 . The difference in Plasma cells (CD38 ϩϩ ) were found in all 25 stem cell colabsolute numbers was also not significantly different lections studied with a mean of 0.7% and a range of 0.03-(t = −0.7, P = 0.5).
2%. CD38
ϩϩ cells were also easily demonstrated in the PBSC harvests of non-myeloma patients. Figure 3 
plots the

Maturity of plasma cells in PBSC harvests
CD45 was used as a marker of maturity of plasma cells. As plasma cells mature they lose CD45 expression. 16, 17 Three clear peaks of CD45 expression in plasma cells were analysed as previously described. 17 These populations were mature plasma cells (CD38 Ϫ cells correlates with the degree of maturity as defined by CD45 expression.
restriction.
Clonal plasma cells identified by CD19
Light chain restriction in plasma cell populations expression Light chain restriction was used as a surrogate marker for clonality. A kappa clone was defined as a ratio of / у 5.0
Several groups have suggested that malignant plasma cells have a CD19
Ϫ /CD56 ϩ phenotype while normal plasma and a lambda clone was defined as a ratio of / р 0.5.
18
Of the 25 patients studied (Figure 5 ), four patients (16%) cells are CD19 ϩ /CD56 Ϫ . 10, 11 We have evaluated this criterion to discriminate between normal and clonal cells in displayed definite plasma cell light chain restriction. These patients also had a relatively high number of CD45 Ϫ PBSC and compared this phenotype with light chain expression in our series of patients. The ratio of CD38 ϩϩ (mature) plasma cells in their PBSC collections (mean 59% of the total plasma cells) and all had progressive disease at CD19
Ϫ plasma cells (normal) was used to deterthe time of PBSC harvest. In contrast, 18 out of 25 patients (72%) had no detectable light chain restriction and had few mine a ratio of malignant/non-malignant plasma cells. Table 1 shows that most of the harvests (n = 14) had low CD45 Ϫ plasma cells (mean 5%). Seventy-six percent of these patients had progressive disease at the time of harvest.
ratios of malignant to non-malignant CD19/CD56 expression. There was concordance between the ratio of Three patients (12%) had a reversed / ratio, one of whom had progressive disease at time of harvest. malignant to non-malignant plasma cells as defined by CD19/CD56 expression and light chain expression in 86% When the analysis was confined to mature plasma cells, light chain restriction was observed in 53% of harvests. In of patients studied. that the process of PBSC mobilisation with chemotherapy and G-or GM-CSF leads to the release of both clonally restricted and polyclonal plasma cells. The cause of this Discussion phenomenon is not known. A large number of reports have now shown that PBSC Plasma cells are present in the PBSC harvests of both myeloma and non-myeloma patients in sufficient numbers to be from patients with myeloma contain malignant cells and many studies have used PCR-based techniques to demonstudied by flow cytometry. The present study has demonstrated that there is considerable heterogeneity in the strate the presence of clonally restricted (malignant) cells. [5] [6] [7] [8] Attempts to quantitate PCR are technically difficult, prone plasma cell population present in PBSC harvests obtained from patients with multiple myeloma. Using a flow cytoto error and do not estimate the residual non-malignant plasma cells. Accurate quantitation of plasma cell numbers metric analysis of cytoplasmic kappa and lambda expression after cell permeabilisation we have demonin PBSC has been performed by flow cytometry using high expression of CD38 as a marker for plasma cells. 10, 13, 14 The strated that for most patients with myeloma, the majority of plasma cells in PBSC harvests are polyclonal. Only a present study is important because it demonstrates that the majority of these CD38 ϩϩ cells in PBSC from myeloma small percentage (16%) of collections clearly demonstrated light chain restriction consistent with the presence of a prepatients are normal plasma cells. Thus studies which infer that CD38 expression in PBSC is related to the number of dominantly clonal population. Studies of CD45 coexpression have shown that PBSC plasma cells are predomimalignant cells must be treated with caution. nantly immature (CD45 ϩ / ϩϩ ) rather than mature (CD45 Ϫ ). An analysis of light chain expression in these plasma cell subpopulations demonstrated that a clonal population was
